SCHEMBL3484983

SCHEMBL3484983

Nc1ccc(Oc2cccc3sccc23)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 5/20 0.46
ERBB2 P04626 5/20 0.46
RHEB Q15382 1/20 0.39
LCK P06239 1/20 0.39
LYN P07948 1/20 0.39
MET P08581 1/20 0.39
BRAF P15056 1/20 0.39
MAP2K5 Q13163 1/20 0.39
ERBB4 Q15303 1/20 0.39
MAPK14 Q16539 1/20 0.39
VEGFA P15692 1/20 0.38
EPAS1 Q99814 2/20 0.36
ESRRA P11474 1/20 0.34
CYP3A4 P08684 2/20 0.34
TSHR P16473 1/20 0.34
PDE7A Q13946 1/20 0.33
CYP2C9 P11712 1/20 0.33
MAPT P10636 2/20 0.32
HPGD P15428 2/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11027863 0.84 EGFR (0.38) EGFRERBB2LCKLYNMET
SCHEMBL3403550 0.78 EGFR (0.48) EGFRERBB2RHEBLCKLYN
SCHEMBL3484299 0.78 KMT2A (0.54) EGFRERBB2CYP3A4PDE7ACYP2C9
SCHEMBL3484572 0.76 ESRRA (0.56) RHEBESRRACYP3A4TSHRHPGD
SCHEMBL1964539 0.76 CYP3A4 (0.56) CYP3A4TSHRPDE7ACYP2C9MAPT
Hydrochloric Acid SCHEMBL10884537 0.75 ESRRA (0.54) RHEBESRRACYP3A4TSHRHPGD
SCHEMBL632218 0.74 CYP3A4 (0.46) EGFRERBB2RHEBERBB4CYP3A4
SCHEMBL22069692 0.73 RHEB (0.45) RHEBCYP3A4TSHRPDE7AMAPT
SCHEMBL1660675 0.72 RHEB (0.37) EGFRERBB2RHEBERBB4ESRRA
SCHEMBL10963610 0.72 ESRRA (0.54) RHEBESRRACYP3A4TSHRPDE7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004238-A1 FUSED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-07 US disclosed
EP-2103620-A1 FUSED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-09-23 EP disclosed
US-4426385-A Insecticidal bicyclooxyphenyl ureas UNION CARBIDE CORPORATION (US) 1984-01-17 US disclosed
EP-0050321-A2 Novel bicyclooxyphenyl ureas, process for their preparation and pesticides containing them UNION CARBIDE CORPORATION (US) 1982-04-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004238-A1 FUSED HETEROCYCLIC COMPOUND ERBB2, ROS1, FLT3 EGFR 13/4885ERBB2 1/4885RHEB 1785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.